Tags

Type your tag names separated by a space and hit enter

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Neurosci Behav Physiol. 2008 Nov; 38(9):933-6.NB

Abstract

Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone. The results obtained in the present study demonstrated the advantages of Stalevo over traditional agents in patients with the "wearing off" and "on-off" phenomena.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Boiko AN
Department of Neurology and Neurosurgery, Russian State Medical University, Moscow, Russia.
Batysheva TT
No affiliation info available
Minaeva NG
No affiliation info available
Babina LA
No affiliation info available
Vdovichenko TV
No affiliation info available
Zhuravleva EY
No affiliation info available
Shikhkerimov RK
No affiliation info available
Malykhina EA
No affiliation info available
Khozova AA
No affiliation info available
Zaitsev KA
No affiliation info available
Kostenko EV
No affiliation info available

MeSH

Activities of Daily LivingAgedAntiparkinson AgentsCarbidopaCatecholsDrug CombinationsDyskinesiasFemaleHumansLevodopaMaleMiddle AgedMotor ActivityOutpatientsParkinson DiseaseSeverity of Illness IndexTime FactorsTreatment Outcome

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

18975095

Citation

Boiko, A N., et al. "Use of the New Levodopa Agent Stalevo (levodopa/carbidopa/entacapone) in the Treatment of Parkinson's Disease in Out-patient Clinical Practice (the START-M Open Trial)." Neuroscience and Behavioral Physiology, vol. 38, no. 9, 2008, pp. 933-6.
Boiko AN, Batysheva TT, Minaeva NG, et al. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neurosci Behav Physiol. 2008;38(9):933-6.
Boiko, A. N., Batysheva, T. T., Minaeva, N. G., Babina, L. A., Vdovichenko, T. V., Zhuravleva, E. Y., Shikhkerimov, R. K., Malykhina, E. A., Khozova, A. A., Zaitsev, K. A., & Kostenko, E. V. (2008). Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neuroscience and Behavioral Physiology, 38(9), 933-6. https://doi.org/10.1007/s11055-008-9085-3
Boiko AN, et al. Use of the New Levodopa Agent Stalevo (levodopa/carbidopa/entacapone) in the Treatment of Parkinson's Disease in Out-patient Clinical Practice (the START-M Open Trial). Neurosci Behav Physiol. 2008;38(9):933-6. PubMed PMID: 18975095.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). AU - Boiko,A N, AU - Batysheva,T T, AU - Minaeva,N G, AU - Babina,L A, AU - Vdovichenko,T V, AU - Zhuravleva,E Yu, AU - Shikhkerimov,R K, AU - Malykhina,E A, AU - Khozova,A A, AU - Zaitsev,K A, AU - Kostenko,E V, PY - 2008/11/1/pubmed PY - 2009/4/3/medline PY - 2008/11/1/entrez SP - 933 EP - 6 JF - Neuroscience and behavioral physiology JO - Neurosci Behav Physiol VL - 38 IS - 9 N2 - Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone. The results obtained in the present study demonstrated the advantages of Stalevo over traditional agents in patients with the "wearing off" and "on-off" phenomena. SN - 0097-0549 UR - https://www.unboundmedicine.com/medline/citation/18975095/Use_of_the_new_levodopa_agent_Stalevo__levodopa/carbidopa/entacapone__in_the_treatment_of_Parkinson's_disease_in_out_patient_clinical_practice__the_START_M_open_trial__ L2 - https://doi.org/10.1007/s11055-008-9085-3 DB - PRIME DP - Unbound Medicine ER -